Advertisement
Advertisement
ASND
Ascendis Pharma A/S Ordinary Share
252.99
USDSponsored
+1.04
+0.41%
Aug 25, 15:57 UTC -4
Closed
Pre-Market
260.00
+7.01
+2.77%
ASND Earnings Reports
Positive Surprise Ratio
ASND beat 16 of 42 last estimates.
38%
Next Report
Date of Next Report
Nov 06, 2026
Estimate for Q3 26 (Revenue/ EPS)
$362.47M
/$1.17
Implied change from Q2 26 (Revenue/ EPS)
--
/--
Implied change from Q3 25 (Revenue/ EPS)
+69.67%
/-217.00%
Ascendis Pharma A/S Ordinary Share earnings per share and revenue
On Aug 05, 2026, ASND reported earnings of -- USD per share (EPS) for Q2 26, -- the estimate of 1.40 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 338.19 million, with a --% difference. The market reacted with a +2.31% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 12 analysts forecast an EPS of 1.17 USD, with revenue projected to reach 362.47 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Alvotech Ordinary Shares
Report Date
Aug 19, 2026 For Q2 26
Estimate
-$0.02
Actual
-$0.11
Surprise
-300.00%
Cabaletta Bio, Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.34
Surprise
+10.69%
Abeona Therapeutics Inc. Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.23
Actual
-$0.35
Surprise
-49.19%
Prenetics Global Limited Class A Ordinary Share
Report Date
Aug 18, 2026 For Q2 26
Estimate
-$0.71
Actual
-$0.53
Surprise
+26.30%
Fate Therapeutics, Inc.
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.27
Actual
-$0.25
Surprise
+8.49%
ProMIS Neurosciences Inc. Common Shares (ON)
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$1.39
Actual
-$1.28
Surprise
+8.07%
TuHURA Biosciences, Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+5.34%
Outlook Therapeutics, Inc. Common Stock
Report Date
Aug 14, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.09
Surprise
+5.46%
Elutia Inc. Class A Common Stock
Report Date
Aug 13, 2026 For Q2 26
Estimate
-$0.15
Actual
-$0.17
Surprise
-11.11%
Lantern Pharma Inc. Common Stock
Report Date
Aug 14, 2026 For Q2 26
Estimate
-$0.38
Actual
-$0.28
Surprise
+27.76%
FAQ
What were Ascendis Pharma A/S Ordinary Share's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Ascendis Pharma A/S Ordinary Share reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Ascendis Pharma A/S Ordinary Share's Q2 2026 earnings?
The stock price moved up 2.31%, changed from $244.20 before the earnings release to $249.85 the day after.
When is Ascendis Pharma A/S Ordinary Share expected to report next?
The next earning report is scheduled for Nov 06, 2026.
What are the forecasts for Ascendis Pharma A/S Ordinary Share's next earnings report?
Based on 12
analysts, Ascendis Pharma A/S Ordinary Share is expected to report EPS of $1.17 and revenue of $362.47M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement